

SpeeDx gets CE-IVD nod for ResistancePlus MG FleXible

09 September 2019 | News

Near-patient Mycoplasma genitalium and macrolide resistance testing now available for sale in European Countries



Australia based SpeeDx Pty, Ltd. has announced **ResistancePlus**®MG FleXible for the Cepheid GeneXpert® System, detecting the sexually transmitted infection (STI) *Mycoplasma genitalium* (Mgen) and markers associated with azithromycin resistance, received CE-IVD mark for sale in Europe.

This is the first test to be launched under Cepheid's FleXible Cartridge programme, partnering with SpeeDx – a trusted assay manufacturer – to provide access to the GeneXpert sample-to-answer FleXible cartridge.

ResistancePlus®MG FleXible will be exclusively distributed by Cepheid.

“ResistancePlus MG FleXible represents both an evolution of our technology and of Resistance Guided Therapy for Mgen”, said Colin Denver SpeeDx CEO. “There is considerable interest by clinicians and laboratories alike, as it will now be even easier to adhere to international and local management guidelines and provide clinically relevant and timely information to manage the growing problem of macrolide resistance in Mgen infections.”